Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

NASDAQ:RVPH - Nasdaq - US76152G1004 - Common Stock - Currency: USD

0.7824  +0.07 (+10.35%)

After market: 0.7577 -0.02 (-3.16%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to RVPH. RVPH was compared to 198 industry peers in the Pharmaceuticals industry. RVPH has a bad profitability rating. Also its financial health evaluation is rather negative. RVPH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RVPH had negative earnings in the past year.
RVPH had a negative operating cash flow in the past year.
In the past 5 years RVPH reported 4 times negative net income.
RVPH had a negative operating cash flow in each of the past 5 years.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of RVPH (-192.99%) is worse than 88.38% of its industry peers.
RVPH has a Return On Equity of -3680.05%. This is amonst the worse of the industry: RVPH underperforms 84.85% of its industry peers.
Industry RankSector Rank
ROA -192.99%
ROE -3680.05%
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

RVPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, RVPH has more shares outstanding
Compared to 5 years ago, RVPH has more shares outstanding
RVPH has a worse debt/assets ratio than last year.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

RVPH has an Altman-Z score of -19.89. This is a bad value and indicates that RVPH is not financially healthy and even has some risk of bankruptcy.
RVPH has a Altman-Z score of -19.89. This is amonst the worse of the industry: RVPH underperforms 82.83% of its industry peers.
RVPH has a Debt/Equity ratio of 0.56. This is a neutral value indicating RVPH is somewhat dependend on debt financing.
RVPH's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. RVPH is outperformed by 62.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -19.89
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RVPH has a Current Ratio of 1.01. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
RVPH's Current ratio of 1.01 is on the low side compared to the rest of the industry. RVPH is outperformed by 81.82% of its industry peers.
RVPH has a Quick Ratio of 1.01. This is a normal value and indicates that RVPH is financially healthy and should not expect problems in meeting its short term obligations.
RVPH has a Quick ratio of 1.01. This is in the lower half of the industry: RVPH underperforms 75.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.51% over the past year.
EPS 1Y (TTM)44.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RVPH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.8%
EPS Next 2Y12.06%
EPS Next 3Y18.23%
EPS Next 5Y24.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

RVPH's earnings are expected to grow with 18.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.06%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (4/17/2025, 8:00:02 PM)

After market: 0.7577 -0.02 (-3.16%)

0.7824

+0.07 (+10.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-12 2025-05-12
Inst Owners29.39%
Inst Owner Change0.12%
Ins Owners10.17%
Ins Owner Change0%
Market Cap36.57M
Analysts81.67
Price Target12.39 (1483.59%)
Short Float %12.79%
Short Ratio2.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.98%
Min EPS beat(2)0.37%
Max EPS beat(2)31.6%
EPS beat(4)4
Avg EPS beat(4)19.75%
Min EPS beat(4)0.37%
Max EPS beat(4)34.93%
EPS beat(8)6
Avg EPS beat(8)-2.76%
EPS beat(12)8
Avg EPS beat(12)-6.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.11%
EPS NQ rev (1m)21.51%
EPS NQ rev (3m)26.01%
EPS NY rev (1m)17.25%
EPS NY rev (3m)22.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 45.04
P/tB 45.04
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -192.99%
ROE -3680.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -19.89
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y25.8%
EPS Next 2Y12.06%
EPS Next 3Y18.23%
EPS Next 5Y24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.43%
OCF growth 3YN/A
OCF growth 5YN/A